SCHEDULE 13G/A: FMR LLC and Abigail P. Johnson Disclose 9.4% Passive Stake in Cartesian Therapeutics Inc.

FMR LLC and its affiliate Abigail P. Johnson have filed an amended Schedule 13G, disclosing a combined beneficial ownership of 9.4% of Cartesian Therapeutics Inc.'s common stock as of December 31, 2024.

Summary

• FMR LLC and Abigail P. Johnson, acting as reporting persons, jointly filed an Amendment No. 1 to Schedule 13G regarding their beneficial ownership in CARTESIAN THERAPEUTICS INC.
• As of December 31, 2024, the aggregate amount beneficially owned by FMR LLC and Abigail P. Johnson is 2,423,213 shares of Common Stock.
• This ownership represents 9.4% of the total outstanding Common Stock of CARTESIAN THERAPEUTICS INC.
• FMR LLC holds sole voting power over 2,423,021 shares and sole dispositive power over 2,423,213 shares.
• Abigail P. Johnson holds sole dispositive power over 2,423,213 shares, with no sole or shared voting power.
• The filing indicates that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer.
• FMR LLC is classified as a Parent Holding Company (HC), and Abigail P. Johnson is classified as an Individual (IN).
• Subsidiaries of FMR LLC, including Fidelity Management & Research Company LLC (Investment Adviser) and Fidelity Management Trust Company (Bank), are identified as entities that beneficially own shares.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive. While a 13G is a factual disclosure, the presence of a significant stake by a reputable institutional investor like FMR LLC can be interpreted as a positive signal of confidence in the company, even if the investment is passive.

Positives

• The disclosure of a significant stake by a major institutional investor like FMR LLC can be viewed as a vote of confidence in Cartesian Therapeutics Inc.
• The passive nature of the investment, as stated in the filing, suggests that FMR LLC is not seeking to influence control, which can provide stability regarding corporate governance.

Risks

• While the filing states the stake is passive and not for control, a large institutional holding always carries the inherent risk of potential future share sales, which could impact stock price.
• The document does not disclose any operational or financial risks specific to Cartesian Therapeutics Inc., as it is an ownership disclosure filing.

Future Outlook

This Schedule 13G filing does not contain any forward-looking statements or guidance regarding Cartesian Therapeutics Inc.'s future outlook or performance.

Industry Context

This filing indicates continued or new interest from a major asset management firm, FMR LLC, in the biotechnology or pharmaceutical sector, represented by Cartesian Therapeutics Inc. Such institutional investment can signal broader market confidence in the sector or specific company prospects, although this filing is purely a disclosure of a passive stake.

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional stake may positively influence investor sentiment and potentially the stock price, indicating institutional confidence.
• Company Management: Awareness of a large, passive institutional holder may influence strategic considerations, though the filing explicitly states no intent to influence control.

Key Dates

Keywords

Cartesian Therapeutics Inc., FMR LLC, Abigail P. Johnson, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, SEC Filing, Ownership Disclosure, Passive Investment